scholarly journals Does insulin therapy lead to an increased risk of cancer in type 2 diabetes mellitus?

2005 ◽  
Vol 22 (3) ◽  
pp. 77-78 ◽  
Author(s):  
James Brown ◽  
Miles Fisher
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Increased Risk ◽  
Risk Of Cancer

scholarly journals The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis

BMJ Open ◽  
2018 ◽  
Vol 8 (11) ◽  
pp. e020062 ◽  
Author(s):  
Xiaosu Bai ◽  
Zhiming Liu ◽  
Zhisen Li ◽  
Dewen Yan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Depressive Disorders ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Cochrane Library ◽  
Increased Risk

ObjectivesSeveral patients with type 2 diabetes mellitus (T2DM) have depressive disorders. Whether insulin treatment was associated with increased risk of depression remains controversial. We performed a meta-analysis to evaluate the association of insulin therapy and depression.DesignA meta-analysis.MethodsWe conducted a systematic search of PubMed, PsycINFO, Embase and the Cochrane Library from their inception to April 2016. Epidemiological studies comparing the prevalence of depression between insulin users and non-insulin users were included. A random-effects model was used for meta-analysis. The adjusted and crude data were analysed.ResultsTwenty-eight studies were included. Of these, 12 studies presented with adjusted ORs. Insulin therapy was significantly associated with increased risk of depression (OR=1.41, 95% CI 1.13 to 1.76, p=0.003). Twenty-four studies provided crude data. Insulin therapy was also associated with an odds for developing depression (OR=1.59, 95% CI 1.41 to 1.80, p<0.001). When comparing insulin therapy with oral antidiabetic drugs, significant association was observed for adjusted (OR=1.42, 95% CI 1.08 to 1.86, p=0.008) and crude (OR=1.61, 95% CI 1.35 to 1.93, p<0.001) data.ConclusionsOur meta-analysis confirmed that patients on insulin therapy were significantly associated with the risk of depressive symptoms.

scholarly journals Noncommunicable disease among adults with cerebral palsy

Neurology ◽  
2019 ◽  
Vol 93 (14) ◽  
pp. e1385-e1396 ◽  
Author(s):  
Jennifer M. Ryan ◽  
Mark D. Peterson ◽  
Anthony Matthews ◽  
Nicola Ryan ◽  
Kimberley J. Smith ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Cerebral Palsy ◽  
Respiratory Disease ◽  
Noncommunicable Disease ◽  
Increased Risk ◽  
Risk Of Cancer

ObjectiveTo compare the incidence of noncommunicable diseases between adults with and without cerebral palsy (CP).MethodsA cohort study was conducted using primary care data from the Clinical Practice Research Datalink. Cox models, stratified by matched set and adjusted for potential confounders, were fitted to compare the risk of any noncommunicable disease, cancer, cardiovascular disease, type 2 diabetes mellitus, and respiratory disease between adults with and without CP.ResultsThe analysis included 1,705 adults with CP and 5,115 age-, sex-, and general practice–matched adults without CP. There was evidence from adjusted analyses that adults with CP had 75% increased risk of developing any noncommunicable disease compared to adults without CP (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.58–1.94). Specifically, they had increased risk of cardiovascular disease (HR 1.76, 95% CI 1.48–2.11) and respiratory disease (HR 2.61, 95% CI 2.14–3.19). There was no evidence of increased risk of cancer or type 2 diabetes mellitus.ConclusionsAdults with CP had increased risk of noncommunicable disease, specifically cardiovascular and respiratory disease. These findings highlight the need for clinical vigilance regarding identification of noncommunicable disease in people with CP and further research into the etiology and management of noncommunicable disease in this population.

scholarly journals DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control

2020 ◽  
Vol 8 (1) ◽  
pp. e001346
Author(s):  
Carlos K H Wong ◽  
Kenneth K C Man ◽  
Esther W Y Chan ◽  
Tingting Wu ◽  
Emily T Y Tse ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Mortality ◽  
Dual Therapy ◽  
Increased Risk ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
All Cause Mortality ◽  
Risk Of Cancer

IntroductionThis study aims to compare the risks of cancer among patients with type 2 diabetes mellitus (T2DM) on metformin–sulfonylurea dual therapy intensified with dipeptidyl peptidase 4 inhibitors (DPP4i), thiazolidinediones, or insulin.Research design and methodsWe assembled a retrospective cohort data of 20 577 patients who were free of cancer and on metformin–sulfonylurea dual therapy, and whose drug treatments were intensified with DPP4i (n=9957), insulin (n=7760), or thiazolidinediones (n=2860) from January 2006 to December 2017. Propensity-score weighting was used to balance out baseline covariates across the three groups. HRs for any types of cancer, cancer mortality, and all-cause mortality were assessed using Cox proportional-hazards models.ResultsOver a mean follow-up period of 34 months with 58 539 person-years, cumulative incidences of cancer, cancer mortality, and all-cause mortality were 0.028, 0.009, and 0.072, respectively. Patients intensified with insulin had the highest incidence of all-cause mortality (incidence rate=3.22/100 person-years) and the insulin itself posed the greatest risk (HR 2.46, 95% CI 2.25 to 2.70, p<0.001; 2.44, 95% CI 2.23 to 2.67) compared with thiazolidinediones and DPP4i, respectively. Comparing between thiazolidinediones and DPP4i, thiazolidinediones was associated with higher risk of cancer (HR 1.43, 95% CI 1.25 to 1.63) but not cancer mortality (HR 1.21, 95% CI 0.92 to 1.58) and all-cause mortality (HR 0.99, 95% CI 0.88 to 1.11). Insulin was associated with the greatest risk of cancer mortality (HR 1.36, 95% CI 1.09 to 1.71; 1.65, 95% CI 1.31 to 2.07) compared with thiazolidinediones and DPP4i, respectively.ConclusionsFor patients with T2DM on metformin–sulfonylurea dual therapy, the addition of DPP4i was the third-line medication least likely to be associated with cancer mortality and cancer effect among three options, and posed no increased risk for all-cause mortality when compared with thiazolidinediones.

scholarly journals Study of the Association Between Antihyperglycemic Therapy and Cancer in Patients with Type 2 Diabetes Mellitus

2020 ◽  
Vol 27 (3) ◽  
pp. E202033
Author(s):  
Tamara Vatseba ◽  
Liubov Sokolova ◽  
Volodymyr Pushkarev ◽  
Nataliia Koshel
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Confidence Interval ◽  
Insulin Therapy ◽  
Odds Ratio ◽  
Antidiabetic Therapy ◽  
Antihyperglycemic Therapy ◽  
Risk Of Cancer

The objective of the research was to investigate the features and association of antihyperglycemic therapy and cancer in patients with type 2 diabetes mellitus. Materials and Methods. The study included the analysis of medical records of patients with type 2 diabetes mellitus who were diagnosed with cancer during 2012-2016. The obtained results were processed by statistical methods using the software packages Microsoft Excel and Statistika-12. The significance of differences between the frequency of using different treatment schemes was assessed by the Pearson’s test (χ²). To determine the risk of predicted events, the odds ratio, the 95% confidence interval, the positive and negative prognostic values were calculated. Results. There were diagnosed 533 cases of cancer in patients with type 2 diabetes mellitus. The most common scheme of antihyperglycemic therapy prior to the detection of malignant diseases was a combination of metformin and sulfonylurea derivatives (35.65%), as well as monotherapy with sulfonylurea derivatives (17.26%) and metformin (11.28%). Prior to diagnosing cancer in 396 (74.30%) patients, antihyperglycemic therapyalong with sulfonylurea derivatives and insulin was used. Among obese patients 68.82% used sulfonylureas and insulin as part of antidiabetic therapy before diagnosis of cancer. The connection between insulin therapy and the risk of cancer development in patients with type 2 diabetes mellitus was proved (the odds ratio=2.35; the 95% confidence interval (1.91 - 2.91); p<0.001). Conclusions. Prior to the detection of cancer in patients with type 2 diabetes mellitus, the combination therapy with metformin and sulfonylurea derivatives was most often used. The association between insulin therapy and the development of cancer in patients with type 2 diabetes mellitus was revealed. Cancer screening is advisable for patients with type 2 diabetes mellitus and obesity, who receive as a therapy sulfonylurea derivates and/or insulin.

scholarly journals Assessment of the prognostic cancer risk in patients with type 2 diabetes mellitus

2021 ◽  
Vol 17 (1) ◽  
pp. 86-91
Author(s):  
T.S. Vatseba ◽  
L.K. Sokolova ◽  
N.M. Koshel
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Risk ◽  
Malignant Neoplasms ◽  
Increased Risk ◽  
Risk Of Cancer ◽  
Prognostic Power ◽  
Uterine Body

Background. The epidemiological analysis has shown an increased risk of cancer of the mammalian gland (MG), ute­rine body, and pancreas in patients with type 2 diabetes mellitus (T2DM). The different clinical characteristics and features of the course of DM, and schemes of treatment of patients with these types of oncological diseases (OD) were identified. The purpose of the study was to create a model of mathematical calculation and assessment of the predicted risk of cancer of MG, uterine body, pancreatic and colorectal cancer (CRC) in patients with T2DM, given the importance of diabetes-associated factors of oncogenesis. Materials and methods. The study included an analysis of medical records of patients with T2DM with first diagnosed OD during 2012–2016. The statistical analysis of the results was performed in the program Statistica 12.0 (StatSoft Inc., USA). The differences between indicators were determined by Student’s t-test, considered significant at p < 0.05. The method of multi-factor analysis and the logistic regression equation was used to calculate the coefficient of prognostic risk of the OD. Results. It was found that cancer of MG and the uterine body was most often diagnosed in people at the age of 60–70 years, with obesity, duration of DM more than 5 years, with HbA1c level > 7.5 %, on combination therapy with drugs without influence on the insulin synthesis with stimulators of insulin production. Patients with CRC had the same characteristics, without gender diffe­rences. Pancreatic cancer was most often diagnosed in patients aged 60–70 years, without obesity, with a duration of DM up to 5 years, with HbA1c > 7.5 %, on monotherapy with insulin or sulfonylureas, without gender differences. The created model for calculating the coefficient of the prognostic risk of MG and uterine body cancer is characterized by high prognostic power (accuracy 76.24 %), good prognostic power for cancer of the pancreas (accuracy 75.0 %), and CRC (accuracy 72.2 %). Conclusions. Correction of dysmetabolic disorders is a method of prevention of OD in patients with T2DM. The calculation of the predicted cancer risk will contribute to the prevention of malignant neoplasms in patients with T2DM.

scholarly journals Decreased Cognitive Function in People with Type 2 Diabetes Mellitus

2021 ◽  
Vol 16 (1) ◽  
pp. 34
Author(s):  
Shinta Kaozar Wiratman ◽  
Widya Hary Cahyati
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cognitive Function ◽  
Blood Sugar ◽  
Cross Sectional ◽  
People With Dementia ◽  
Increased Risk ◽  
Risk Of Cancer

ABSTRACTBackground: The number of cases and the prevalence of diabetes has continued to increase over the past few decades. DM itself is associated with an increased risk of cancer, kidney failure, stroke, and decreased cognitive function that leads to dementia. In 2016 Indonesia has an estimated 1.2 million people with dementia and is expected to grow to 4 million by 2050.Objective: The purpose of this study was to find out the risk factors for decreased cognitive function in people with type 2 diabetes mellitus.Method: This type of research is observational analytics with cross sectional design. The sample was 62 respondents with purposive sampling techniques. The instrument used in the study was a structured questionnaire. Measurement of cognitive function using MoCA-INA questionnaire. Data collection is done by interview method to respondents.Result: The results showed that there was a relationship between the age of the respondent (PR= 2.98; 95% CI= 0.97-9.17), and the respondent's blood sugar level (PR= 3.31; 95% CI= 1.12-9.74) to decreased cognitive function in people with type 2 diabetes mellitus.Conclusion: Age and blood sugar levels of respondents contributed to decreased cognitive function of people with type 2 diabetes mellitus.

Efficacy and Safety of Continuing Sitagliptin when Initiating Insulin Therapy in Subjects with Type 2 Diabetes Mellitus

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 112-LB ◽  
Author(s):  
RONAN ROUSSEL ◽  
SANTIAGO DURAN-GARCIA ◽  
YILONG ZHANG ◽  
SUNERI SHAH ◽  
CAROLYN DARMIENTO ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Efficacy And Safety

The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis

2018 ◽  
Vol 15 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Sayantan Nath ◽  
Sambuddha Das ◽  
Aditi Bhowmik ◽  
Sankar Kumar Ghosh ◽  
Yashmin Choudhury
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Meta Analysis ◽  
Subsequent Development ◽  
Asian Population ◽  
Gstm1 Null Genotype ◽  
Increased Risk

Background:Studies pertaining to association of GSTM1 and GSTT1 null genotypes with risk of T2DM and its complications were often inconclusive, thus spurring the present study.Methods:Meta-analysis of 25 studies for evaluating the role of GSTM1/GSTT1 null polymorphisms in determining the risk for T2DM and 17 studies for evaluating the role of GSTM1/GSTT1 null polymorphisms in development of T2DM related complications were conducted.Results:Our study revealed an association between GSTM1 and GSTT1 null polymorphism with T2DM (GSTM1; OR=1.37;95% CI =1.10-1.70 and GSTT1; OR=1.29;95% CI =1.04-1.61) with an amplified risk of 2.02 fold for combined GSTM1-GSTT1 null genotypes. Furthermore, the GSTT1 null (OR=1.56;95%CI=1.38-1.77) and combined GSTM1-GSTT1 null genotypes (OR=1.91;95%CI=1.25- 2.94) increased the risk for development of T2DM related complications, but not the GSTM1 null genotype. Stratified analyses based on ethnicity revealed GSTM1 and GSTT1 null genotypes increase the risk for T2DM in both Caucasians and Asians, with Asians showing much higher risk of T2DM complications than Caucasians for the same. </P><P> Discussion: GSTM1, GSTT1 and combined GSTM1-GSTT1 null polymorphism may be associated with increased risk for T2DM; while GSTT1 and combined GSTM1-GSTT1 null polymorphism may increase the risk of subsequent development of T2DM complications with Asian population carrying an amplified risk for the polymorphism.Conclusion:Thus GSTM1 and GSTT1 null genotypes increases the risk for Type 2 diabetes mellitus alone, in combination or with regards to ethnicity.

Sign in / Sign up

Export Citation Format

Share Document